BioStock has published the article: “Ultimovacs in the fight against Melanoma”:

“Melanoma is the deadliest form of skin cancer. As such, new treatments for the disease are in strong demand. Norwegian immuno-oncology experts Ultimovacs are developing a type of cancer vaccine able to boost a patient’s immune system during cancer, and their top candidate UV1 is being tested in a phase I clinical trial and a phase II proof-of-concept study with different combination therapies in malignant melanoma patients. BioStock was able to get in touch with the company’s CMO Jens Bjørheim, and Senior Medical Advisor Steinar Aamdal to learn more about the disease and the phase I study, which recently produced results.”

Read the full article here

About BioStock
BioStock is a leading Nordic digital news and analytics service focusing exclusively on the life science sector.